• Profile
Close

A comparative effectiveness study of degludec and insulin glargine 300 U/mL in insulin-naïve patients with type 2 diabetes

Diabetes, Obesity and Metabolism Jan 18, 2019

Tibaldi J, et al. - In routine US clinical practice, researchers compared the real-world effectiveness of insulin degludec (degludec) vs glargine 300 units/mL (glargine U300) in insulin-naïve adult patients with type 2 diabetes. The primary endpoint, HbA1c change from baseline to 180 days of follow-up, was estimated using a repeated-measure of covariance analysis with subjects as a random effect. Using negative binomial and logistic regression, change in the rate of hypoglycemic episodes and change in proportion of patients with hypoglycemia were estimated. Data were analyzed for 4,056 patients. The results obtained from the CONFIRM (Clinical Outcome assessmeNt of the eFfectiveness of Insulin degludec in Real-life Medical practice) study indicate that degludec treatment results in significantly greater reductions in HbA1c with a 30% lower risk of hypoglycemia and reduced likelihood of discontinuation of treatment vs glargine U300.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay